本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Inozyme Pharma

4.00
0.0000
成交量:- -
成交額:583.41萬
市值:2.60億
市盈率:-2.38
高:4.00
開:4.00
低:4.00
收:4.00
52周最高:6.24
52周最低:0.7210
股本:6,491.57萬
流通股本:3,014.82萬
量比:- -
換手率:- -
股息:- -
股息率:- -
每股收益(TTM):-1.6822
每股收益(LYR):-1.6243
淨資產收益率:-141.69%
總資產收益率:-48.45%
市淨率:8.17
市盈率(LYR):-2.46

資料載入中...

2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/10

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/07

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/11/15

重要事件披露

8-K - Current report
2021/11/15

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/11/09

重要事件披露

8-K - Current report
2021/11/09

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/08/19

SEC問詢函

CORRESP [Cover] - Correspondence
2021/08/11

重要事件披露

8-K - Current report
2021/08/11

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/07/30

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/06/24

重要事件披露

8-K - Current report
2021/05/12

重要事件披露

8-K - Current report
2021/05/12

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/05/10

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/05/07

重要事件披露

8-K - Current report
2021/04/21

重要事件披露

8-K - Current report
2021/03/30

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/03/25

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans